Pendopharm®? and Kalvista®? Partner to Bring First Oral On-Demand HAE Treatment to Canada

Published: 2025-06-27 02:05:35 ET KALV

Published on 06/27/2025 at 02:05

Pendopharm®?, a division of Pharmascience Inc., has entered into an exclusive distribution agreement with KalVista Pharmaceuticals, Inc. This agreement grants Pendopharm®? the rights to manage regulatory approval and commercialization of sebetralstat, an investigational oral therapy for hereditary angioedema (HAE), developed by KalVista®? in Canada.

Financial details of the agreement remain confidential. Sebetralstat is poised to become the first oral on-demand treatment for hereditary angioedema in Canada. This treatment addresses a critical need for patients living with HAE - a rare and potentially life-threatening genetic disorder marked by unpredictable episodes of severe swelling.

Sebetralstat is an investigational oral therapy developed for the on-demand treatment of acute HAE attacks. It is currently under regulatory review in several countries as a potential oral therapy for hereditary Angioedema (HAE). HAE is severe swelling (angioedema) in various parts of the body, including the hands, feet, sexual, stomach, face and/or throat.

Welling in the airway can restrict breathing and be fatal. The vast majority of people with HAE have a genetic defect that causes a deficiency in the plasma protein called C1-Inhibitor. HAE is also seen in people who have normal levels of C1-Inhibitor, however, genetic defects in other genes cause their angioedema.